Birth Cohort: Development of IgE Autoantibodies in Newborns With (High Risk of) Atopic Dermatitis

Recruiting N/A Interventional Study
Atopic Dermatitis (AD) Autoantibody Auto-Immunity Microbiome, Human Allergic Disease IgE-Mediated Hypersensitivity Newborn Infant
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Healthy Volunteers Welcome You do not need to have the condition being studied to take part.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
1 Hour – 24 Months
Sex
Any
Study type
Interventional
Purpose
Basic Science
Participants needed
500 (estimated)
Sponsor
Universitair Ziekenhuis Brussel · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Previous research has shown that some patients with atopic eczema have specific self-reactive antibodies, known as IgE autoantibodies, that react to their own skin cells, referred to as "self-reactive antibodies" or "autoantibodies". It is not yet known when and how these self-reactive antibodies develop, so this is what we aim to investigate. This study aims to examine the presence of self-react…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: Newborns who are planned to be born at the maternity ward of UZ Brussel with the following criteria: * 400 newborns with high-risk for AD-development (at least 1 parent or sibling with physician diagnosed atopic dermatitis AND/OR asthma AND/OR allergic rhinitis) * 100 newborns …
Contacts

Inge Kortekaas Krohn, PhD

+32 (0)2 477 4244

inge.kortekaas@vub.be

CONTACT

Carine Vleminckx

carine.vleminckx@uzbrussel.be

CONTACT